[go: up one dir, main page]

WO2025019800A1 - Nouveaux promédicaments et conjugués de diméthyltryptamine et leurs procédés d'utilisation - Google Patents

Nouveaux promédicaments et conjugués de diméthyltryptamine et leurs procédés d'utilisation Download PDF

Info

Publication number
WO2025019800A1
WO2025019800A1 PCT/US2024/038804 US2024038804W WO2025019800A1 WO 2025019800 A1 WO2025019800 A1 WO 2025019800A1 US 2024038804 W US2024038804 W US 2024038804W WO 2025019800 A1 WO2025019800 A1 WO 2025019800A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
hydrogen
compound
chr
absent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/038804
Other languages
English (en)
Inventor
Tanweer A. Khan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atai Therapeutics Inc
Original Assignee
Atai Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atai Therapeutics Inc filed Critical Atai Therapeutics Inc
Publication of WO2025019800A1 publication Critical patent/WO2025019800A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Definitions

  • DMT 7V,7V-dimethyltryptamine
  • ayahuasca the hallucinogenic infusion known as ayahuasca
  • DMT has a rapid onset, intense psychedelic effects, and a relatively short duration of action with an estimated half-life of less than fifteen minutes.
  • DMT binds to serotonin receptors to produce euphoria and psychedelic effects.
  • MAO monoamine oxidases
  • the present disclosure provides a compound of Formula I:
  • Ri and R2 are each independently hydrogen, alkyl, cycloalkyl, or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring;
  • X, Y and Z are each independently hydrogen, halogen, -O-, -S-, -NR7-, or - CH 2 -;
  • W is oxygen, sulfur or NRe
  • R 7 is hydrogen or alkyl
  • R 9 is hydrogen, alkyl, or halogen
  • the present disclosure provides compounds of Formula IV: or a pharmaceutically acceptable salt thereof; wherein,
  • Ri and R2 are each independently hydrogen, alkyl, cycloalkyl, -or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring;
  • X, Y and Z are each independently hydrogen, halogen, -O-, -S-, -NR 7 -, or - CH 2 -;
  • R 7 is hydrogen or alkyl
  • RA and RB are each independently hydrogen, alkyl, heteroalkyl, cycloalkyl, alkoxy, hemiacetal, ketal, or am amino acid; m is an integer from 1-4; and
  • A- is a pharmaceutically acceptable anion.
  • the term “about” when immediately preceding a numerical value means a range (e.g., plus or minus 10% of that value).
  • “about 50” can mean 45 to 55
  • “about 25,000” can mean 22,500 to 27,500, etc., unless the context of the disclosure indicates otherwise, or is inconsistent with such an interpretation.
  • “about 50” means a range extending to less than half the interval(s) between the preceding and subsequent values, e.g., more than 49.5 to less than 50.5.
  • the phrases “less than about” a value or “greater than about” a value should be understood in view of the definition of the term “about” provided herein.
  • the term “about” when preceding a series of numerical values or a range of values refers, respectively to all values in the series, or the endpoints of the range.
  • administer refers to administering a compound or pharmaceutically acceptable salt of the compound or a composition or formulation comprising the compound or pharmaceutically acceptable salt of the compound to a patient.
  • pharmaceutically acceptable salts includes both acid and base addition salts.
  • Pharmaceutically acceptable salts include those obtained by reacting the active compound functioning as a base, with an inorganic or organic acid to form a salt, for example, salts of hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, camphorsulfonic acid, oxalic acid, maleic acid, succinic acid, citric acid, formic acid, hydrobromic acid, benzoic acid, tartaric acid, fumaric acid, salicylic acid, mandelic acid, carbonic acid, etc.
  • a salt for example, salts of hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, camphorsulfonic acid, oxalic acid, maleic acid, succinic acid, citric acid, formic acid, hydrobromic acid, benzoic acid, tartaric acid, fumaric acid, salicylic acid, mandelic acid, carbonic acid, etc.
  • the acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmaceutically acceptable anions, including but not limited to malate, oxalate, chloride, bromide, iodide, nitrate, acetate, tartrate, oleate, fumarate, formate, benzoate, glutamate, methanesulfonate, benzenesulfonate, and p-toluenesulfonate salts.
  • non-toxic acid addition salts i.e., salts containing pharmaceutically acceptable anions, including but not limited to malate, oxalate, chloride, bromide, iodide, nitrate, acetate, tartrate, oleate, fumarate, formate, benzoate, glutamate, methanesulfonate, benzenesulfonate, and p-toluene
  • Base addition salts include but are not limited to, ethylenediamine, N-methyl-glucamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris-(hydroxymethyl)- aminomethane, tetramethylammonium hydroxide, triethylamine, dibenzylamine, ephenamine, dehydroabietylamine, N-ethylpiperidine, benzylamine, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, ethylamine, basic amino acids, e.
  • lysine and arginine dicyclohexylamine and the like examples include lithium, sodium, potassium, magnesium, calcium salts and the like.
  • metal salts include lithium, sodium, potassium, magnesium, calcium salts and the like.
  • ammonium and alkylated ammonium salts include ammonium, methylammonium, dimethylammonium, trimethylammonium, ethylammonium, hydroxyethylammonium, diethylammonium, butylammonium, tetramethylammonium salts and the like.
  • organic bases include lysine, arginine, guanidine, diethanolamine, choline and the like.
  • treating refers to improving at least one symptom of the patient's disorder.
  • treating can be improving, or at least partially ameliorating a disorder or one or more symptoms of a disorder.
  • preventing refers to preventing the onset of disease development if none had occurred, preventing the disease or disorder from occurring in a subject or a patient that may be predisposed to the disorder or disease but has not yet been diagnosed as having the disorder or disease, and/or preventing further disease/disorder development if already present.
  • terapéuticaally effective applied to dose or amount refers to that quantity of a compound or pharmaceutical formulation that is sufficient to result in a desired clinical benefit after administration to a patient in need thereof.
  • Ci-Ce alkyl is intended to encompass Ci, C2, C3, C4, C5, C 6 , C1-6, Ci-5, C1-4, C1-3, C1-2, C2-6, C2-5, C2-4, C2-3, C3-6, C3.5, C3-4, C4-6, C4-5, and C 5.6 alkyl.
  • Alkyl or “alkyl group” refers to a fully saturated, straight or branched hydrocarbon chain having from one to twelve carbon atoms, and which is attached to the rest of the molecule by a single bond. Alkyls comprising any number of carbon atoms from 1 to 12 are included. An alkyl comprising up to 12 carbon atoms is a C1-C12 alkyl, an alkyl comprising up to 10 carbon atoms is a C1-C10 alkyl, an alkyl comprising up to 6 carbon atoms is a Ci-Ce alkyl and an alkyl comprising up to 5 carbon atoms is a C1-C5 alkyl.
  • a C1-C5 alkyl includes C5 alkyls, C4 alkyls, C3 alkyls, C2 alkyls and Ci alkyl (i.e., methyl).
  • a Ci-Ce alkyl includes all moieties described above for C1-C5 alkyls but also includes Ce alkyls.
  • a C1-C10 alkyl includes all moieties described above for C1-C5 alkyls and Ci-Ce alkyls, but also includes C7, Cs, C9 and C10 alkyls.
  • a C1-C12 alkyl includes all the foregoing moieties, but also includes Cn and C12 alkyls.
  • Ci- C12 alkyl include methyl, ethyl, //-propyl, z-propyl, ec-propyl, //-butyl, z-butyl, sec-butyl, /-butyl, //-pentyl, /-amyl, //-hexyl, //-heptyl, //-octyl, //-nonyl, //-decyl, //-undecyl, and n- dodecyl.
  • an alkyl group can be optionally substituted.
  • Aryl refers to a hydrocarbon ring system comprising hydrogen, 6 to 18 carbon atoms and at least one aromatic ring, and which is attached to the rest of the molecule by a single bond.
  • the aryl can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused or bridged ring systems.
  • Aryls include, but are not limited to, aryls derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as- indacene, -indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene. Unless stated otherwise specifically in the specification, the “aryl” can be optionally substituted.
  • Cycloalkyl refers to a stable non-aromatic monocyclic or polycyclic fully saturated hydrocarbon consisting solely of carbon and hydrogen atoms, which can include fused, bridged, or spirocyclic ring systems, having from three to twenty carbon atoms (e.g., having from three to ten carbon atoms) and which is attached to the rest of the molecule by a single bond.
  • Monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • Polycyclic cycloalkyls include, for example, adamantyl, norbomyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Unless otherwise stated specifically in the specification, a cycloalkyl group can be optionally substituted.
  • Heterocyclic ring or “heterocycle” refers to a stable saturated, unsaturated, or aromatic 3- to 20-membered ring which consists of two to nineteen carbon atoms and from one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and which is attached to the rest of the molecule by a single bond.
  • Heterocyclic rings include heteroaryls, heterocyclylalkyls, heterocyclylalkenyls, and hetercyclylalkynyls.
  • the heterocyclic ring can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused, bridged, or spirocyclic ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclic ring can be optionally oxidized; the nitrogen atom can be optionally quatemized; and the heterocyclic ring can be partially or fully saturated.
  • heterocyclic rings include, but are not limited to, dioxolanyl, thienyl[l,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorph
  • Heteroaryl refers to a 5- to 20-membered ring system comprising hydrogen atoms, one to nineteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, at least one aromatic ring, and which is attached to the rest of the molecule by a single bond.
  • the heteroaryl can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl can be optionally oxidized; the nitrogen atom can be optionally quaternized.
  • Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodi oxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[Z>][l,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodi oxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[l,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophen
  • substituted means any of the groups described herein (e.g., alkyl, aryl, cycloalkyl, heterocyclic ring, and/or heteroaryl) wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atoms such as, but not limited to: a halogen atom such as F, Cl, Br, and I; an oxygen atom in groups such as hydroxyl groups, alkoxy groups, and ester groups; a sulfur atom in groups such as thiol groups, thioalkyl groups, sulfone groups, sulfonyl groups, and sulfoxide groups; a nitrogen atom in groups such as amines, amides, alkylamines, dialkylamines, arylamines, alkylarylamines, diarylamines, N-oxides, imides, and enamines; a silicon atom in groups such as trialkylsilyl
  • “Substituted” also means any of the above groups in which one or more hydrogen atoms are replaced by a higher-order bond (e.g., a double- or triple-bond) to a heteroatom such as oxygen in oxo, carbonyl, carboxyl, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitriles.
  • a higher-order bond e.g., a double- or triple-bond
  • nitrogen in groups such as imines, oximes, hydrazones, and nitriles.
  • R g Rh, -OR g , -SR g , -SOR g , -SO 2 R g , -OSO 2 R g , -SO 2 OR g , NSO 2 R g , and -SO 2 NR g R h .
  • R g and Rh are the same or different and independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclic ring, A-heterocyclic ring, heterocyclylalkyl, heteroaryl, /f-heteroaryl and/or heteroarylalkyl.
  • “Substituted” further means any of the above groups in which one or more hydrogen atoms are replaced by a bond to an amino, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclic ring, A-heterocyclyl, heterocyclylalkyl, heteroaryl, 7V-heteroaryl and/or heteroarylalkyl group.
  • each of the foregoing substituents can also be optionally substituted with one or more of the above substituents.
  • the present disclosure provides compounds that are prodrugs of tryptamines and related scaffolds, for example /f-dimethyltryptarnine (DMT) as well as pharmaceutical compositions thereof.
  • DMT /f-dimethyltryptarnine
  • DMT is metabolically unstable and is readily converted by monoamine oxidases (MAO’s) to indoleacetic acid and A-oxidation metabolites resulting in poor oral bioavailability.
  • MAO monoamine oxidases
  • the compounds of the present disclosure allow for the controlled release of DMT.
  • Advantages of compounds of the present disclosure may include increased metabolic stability, increased absorption, decreased maximal plasma concentrations of parent drug DMT over time, and less frequent dosing.
  • compounds of the present disclosure prevent or inhibit A -oxidation to promote oral bioavailability and increased exposure.
  • compounds of the present disclosure comprise an enacarbil moiety.
  • such compounds may for example, increase bioavailability by virtue of active transport of the prodrug in the small intestine by high-capacity nutrient transporters, including mono-carboxylate transporter-1 (MCT-1).
  • MCT-1 mono-carboxylate transporter-1
  • DMT-enacarbil prodrugs may also reduce abuse potential by preventing absorption by snorting or insufflation.
  • the present disclosure provides prodrugs of tryptamines (e.g., DMT) and derivatives thereof.
  • the present disclosure provides compounds of Formulas I, II, III, and IV.
  • the present disclosure provides a compound of Formula I:
  • Ri and R2 are each independently hydrogen, alkyl, cycloalkyl, or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring;
  • X, Y and Z are each independently hydrogen, halogen, -O-, -S-, -NR7-, or -CH2-;
  • W is oxygen, sulfur or NRe
  • R 7 is hydrogen or alkyl
  • R 9 is hydrogen, alkyl, or halogen
  • the present disclosure provides compounds of Formula (la): or a pharmaceutically acceptable salt thereof, wherein:
  • Ri and R 2 are each both are methyl
  • X, Y, and Z are each either absent or -O-;
  • Ri and R2 are each independently alkyl, cycloalkyl, or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring. In embodiments, Ri and R2 are each independently hydrogen, cycloalkyl, or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring. In embodiments, Ri and R2 are each independently hydrogen, alkyl, or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring. In embodiments, Ri and R2 are each independently hydrogen, alkyl, or cycloalkyl.
  • Ri and R2 are each independently hydrogen or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring. In embodiments, Ri and R2 are each independently cycloalkyl or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring. In embodiments, Ri and R2 are each independently alkyl or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring. In embodiments, Ri and R2 are each independently alkyl or cycloalkyl. In embodiments, Ri and R2 are each independently hydrogen or cycloalkyl. In embodiments, Ri and R2 are each independently hydrogen or alkyl.
  • Ri and R2 are each alkyl. In embodiments, Ri and R2 are each hydrogen. In embodiments, one of Ri and R2 is hydrogen and one of Ri and R2 is alkyl.
  • Ri and R2 together with the atoms to which they are attached form a heterocyclic ring.
  • the heterocyclic ring is a monocyclic, bicyclic, tricyclic, or tetracyclic ring.
  • the heterocyclic ring is a monocyclic ring.
  • the heterocyclic ring is a bicyclic ring.
  • the heterocyclic ring is a tricyclic ring.
  • the heterocyclic ring is a tetracyclic ring.
  • X, Y and Z are each independently halogen, -O-, -S-, -NR?-,or - CH2-. In embodiments, X, Y and Z are each independently hydrogen, -O-, -S-, -NR7-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, halogen, -S-, - NR7-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, halogen, -O-, -NR7-, or -CH2-.
  • X, Y and Z are each independently hydrogen, halogen, -O-, -S-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, halogen, -O-, -S-, or -NR7-.
  • X, Y and Z are each independently -O-, -S-, -NR7-, or -CH2-. In embodiments, X, Y and Z are each independently halogen, -S-, -NR7-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, halogen, -O-, -NR7-, or - CH2-. In embodiments, halogen, -O-, -S-, or -CH2-. In embodiments, halogen, -O-, - S-, or -NR7-.
  • X, Y and Z are each independently hydrogen, -S-, -NR7-, or -CH2- In embodiments, X, Y and Z are each independently hydrogen, -O-, -NR7-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, -O-, -S-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, -O-, -S-, or -NR7-. In embodiments, X, Y and Z are each independently hydrogen, halogen, -NR7-, or -CH2-.
  • X, Y and Z are each independently hydrogen, halogen, -S-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, halogen, -S-, or -NR7-. In embodiments, X, Y and Z are each independently hydrogen, halogen, -O-, or -S-.
  • X, Y and Z are each independently -S-, -NR7-, or -CH2-. In embodiments, X, Y and Z are each independently -O-, -NR7-, or-CH2- In embodiments, X, Y and Z are each independently -O-, -S-, or -CH2-. In embodiments, X, Y and Z are each independently -O-, -S-, or -NR7-. In embodiments, X, Y and Z are each independently hydrogen, -NR7-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, -S-, or -CH2-.
  • X, Y and Z are each independently hydrogen -S-, or -NR7-. In embodiments, X, Y and Z are each independently hydrogen, halogen, or -CH2-. X, Y and Z are each independently hydrogen, halogen, or -NR7-. In embodiments, X, Y and Z are each independently hydrogen, halogen, or -O-.
  • X, Y and Z are each independently hydrogen or halogen. In embodiments, X, Y, and Z are each independently hydrogen or -O-. In embodiments, X, Y, and Z are each independently hydrogen or -S-. In embodiments, X, Y, and Z are each independently hydrogen or -NR7-. In embodiments, X, Y, and Z are each independently hydrogen or -CH2-.
  • X, Y and Z are each independently halogen or -O-. In embodiments,
  • X, Y and Z are each independently halogen or -S-. In embodiments, X, Y and Z are each independently halogen or -NR7-. In embodiments, X, Y and Z are each independently halogen or -CH2-.
  • X, Y, and Z are each independently -O- or -S-, In embodiments, X,
  • Y, and Z are each independently -O- or -NR7-. In embodiments, Z, Y, and Z are each independently -O- or -CH -. In embodiments, X, Y, and Z are each independently -S- or -NR7-. In embodiments, Z, Y, and Z are each independently -S- or -CH2-.
  • X is hydrogen. In embodiments, X is halogen. In embodiments, X is -O-. In embodiments, X is -S-. In embodiments, X is -NR7-. In embodiments, X is - CH2-.
  • Y is hydrogen. In embodiments, Y is halogen. In embodiments, Y is -O-. In embodiments, Y is -S-. In embodiments, Y is -NR7-. In embodiments, Y is - CH2-.
  • Y is hydrogen.
  • Z is halogen.
  • Z is -O-.
  • Z is -S-.
  • Z is -NR7-.
  • Z is - CH2-.
  • R3 and R4 are hydrogen and Rs is alkyl.
  • R3 and Rs are hydrogen and R4 is alkyl.
  • R4 and Rs are hydrogen and R3 is alkyl.
  • R3, R4, and R5 are each hydrogen.
  • R3 and R4 are hydrogen
  • R5 is hydrogen
  • X and Y are absent
  • Z is -O-.
  • R3 and R4 are hydrogen, R5 is alkyl, X and Y are absent, and Z is -O-
  • R3 and R5 are hydrogen, R4 is hydrogen, X and Z are absent, and Y is -O-.
  • R3 and R5 are hydrogen, R4 is alkyl, X and Z are absent, and Y is -O-
  • R4 and R5 are hydrogen, R3 is hydrogen, Y and Z are absent, and X is -O-.
  • R4 and R5 are hydrogen, R3 is alkyl, Y and Z are absent, and X is -O-
  • W is oxygen or sulfur. In embodiments, W is oxygen or NRe. In embodiments, W is sulfur or NRe. In embodiments, W is oxygen. In embodiments, W is sulfur. In embodiments, W is NRe.
  • R 7 is hydrogen. In embodiments, R 7 is alkyl. In embodiments, R 7 is a Ci-Ce alkyl. In embodiments, R 7 is a Ci alkyl. In embodiments, R 7 is a C 2 alkyl. In embodiments, R 7 is a C 3 alkyl.
  • RA, RB, and R c are each independently alkyl, heteroalkyl, cycloalkyl, alkoxy, hemiacetal, ketal, or an amino acid. In embodiments, RA, RB, and R c are each independently hydrogen, heteroalkyl, cycloalkyl, alkoxy, hemiacetal, ketal, or an amino acid. In embodiments, RA, RB, and Re are each independently hydrogen, alkyl, cycloalkyl, alkoxy, hemiacetal, ketal, or an amino acid.
  • RA, RB, and R c are each independently hydrogen, alkyl, heteroalkyl, alkoxy, hemiacetal, ketal, or an amino acid. In embodiments, RA, RB, and R c are each independently hydrogen, alkyl, heteroalkyl, cycloalkyl, hemiacetal, ketal, or an amino acid. In embodiments, RA, RB, and R c are each independently hydrogen, alkyl, heteroalkyl, cycloalkyl, alkoxy, ketal, or an amino acid.
  • RA, RB, and R c are each independently hydrogen, alkyl, heteroalkyl, cycloalkyl, alkoxy, hemiacetal, or an amino acid. In embodiments, RA, RB, and Rc are each independently hydrogen, alkyl, heteroalkyl, cycloalkyl, alkoxy, hemiacetal, or ketal.
  • RA, RB, and Rc are each hydrogen. In embodiments, RA and R c are each hydrogen. In embodiments, RA and RB are each hydrogen. In embodiments, RB and Rc are each hydrogen.
  • RA, RB, and R c are each alkyl. In embodiments, RA and Rc are each alkyl. In embodiments, RA and RB are each alkyl. In embodiments, RB and R c are each alkyl.
  • RA is hydrogen.
  • RB is hydrogen.
  • Rc is hydrogen.
  • RA is hydrogen and RB is alkyl. In embodiments, RA is alkyl and RB is hydrogen.
  • Rc is hydrogen. In embodiments Rc is alkyl.
  • Rs is hydrogen. In embodiments, Rs is alkyl. In embodiments, Rs is Ci-Ce alkyl. In embodiments, Rs is Ci alkyl. In embodiments, Rs is C2 alkyl. In embodiments, Rs is C3 alkyl. In embodiments, Rs is a C4 alkyl. In embodiments, Rs is C5 alkyl. In embodiments, Rs is Ce alkyl.
  • R9 is hydrogen, alkyl, or halogen. In embodiments, R9 is hydrogen. In embodiments, R9 is alkyl. In embodiments, R9 is halogen.
  • m is an integer from 1-4. In embodiments, m is 1. In embodiments, m is 2. In embodiments, m is 3. In embodiments, m is 4.
  • Ri and R2 are alkyl
  • X and Z are hydrogen
  • Y is -O-
  • R3 and Rs are absent.
  • Ri and R2 are alkyl
  • X and Z are hydrogen
  • Y is -O-
  • R3 and R5 are absent
  • W is NRe
  • Re is hydrogen
  • Rs is hydrogen
  • R9 is hydrogen.
  • Ri and R2 are alkyl
  • Y and Z are hydrogen
  • X is -O-
  • R4 and Rs are absent.
  • Ri and R2 are alkyl
  • X and Y are hydrogen
  • Z is -O-
  • R3 and R4 are absent
  • W is NRe
  • Re is hydrogen
  • Rs is hydrogen
  • R9 is hydrogen.
  • Ri and R2 are alkyl
  • X and Z are hydrogen
  • Y is -O-
  • R4 is alkyl
  • R3 and Rs are absent.
  • Ri and R2 are alkyl
  • X and Z are hydrogen
  • Y is -O-
  • R4 is alkyl
  • R3 and R5 are absent
  • W is NRe
  • Re is hydrogen
  • Rs is hydrogen
  • R9 is hydrogen.
  • Ri and R2 are alkyl
  • Y and Z are hydrogen
  • X is -O-
  • R3 is alkyl
  • R4 and Rs are absent.
  • Ri and R2 are alkyl
  • Y and Z are hydrogen
  • X is -O-
  • R3 is alkyl
  • R4 and R5 are absent
  • W is NRe
  • Re is hydrogen
  • Rs is hydrogen
  • R9 is hydrogen.
  • Ri and R2 are alkyl
  • X and Y are hydrogen
  • Z is -O-
  • R5 is alkyl
  • R3 and R4 are absent.
  • Ri and R2 are alkyl
  • X and Y are hydrogen
  • Z is -O-
  • R5 is alkyl
  • R3 and R4 are absent
  • W is NRe
  • Re is hydrogen
  • Rs is hydrogen
  • R9 is hydrogen.
  • Ri and R2 are alkyl
  • X and Z are hydrogen
  • Y is -O-
  • R4 is hydrogen
  • R3 and Rs are absent.
  • Ri and R2 are alkyl
  • X and Z are hydrogen
  • Y is -O-
  • R4 is hydrogen
  • R3 and Rs are absent
  • W is NRe
  • Re is hydrogen
  • Rs is hydrogen
  • R9 is hydrogen.
  • Ri and R2 are alkyl
  • Y and Z are hydrogen
  • X is -O-
  • R3 is hydrogen
  • R4 and Rs are absent.
  • Ri and R2 are alkyl
  • Y and Z are hydrogen
  • X is -O-
  • R3 is hydrogen
  • R4 and Rs are absent
  • W is NRe
  • Re is hydrogen
  • Rs is hydrogen
  • R9 is hydrogen
  • Ri and R2 are alkyl
  • X and Y are hydrogen
  • Z is -O-
  • Rs is hydrogen
  • R3 and R4 are absent.
  • Ri and R2 are alkyl, X and Y are hydrogen, Z is -O-, Rs is hydrogen, R3 and R4 are absent, W is NRe, Re is hydrogen, Rs is hydrogen, and R9 is hydrogen.
  • Ri and R2 are alkyl, X, Y, and Z are hydrogen, and R3, R4, and R5 are absent.
  • Ri and R2 are alkyl, X, Y, and Z are hydrogen, and R3, R4, and R5 are absent, W is NRe, Re is hydrogen, Rs is hydrogen, and R9 is hydrogen.
  • Ri and R2 are alkyl
  • X, Y, and Z are hydrogen
  • R3, R4, and R5 are absent
  • W is NRe
  • Ri and R2 are alkyl
  • X, Y, and Z are hydrogen
  • R3, R4, and R5 are absent
  • W is NRe
  • Rs is hydrogen
  • R9 is hydrogen.
  • Ri and R2 are alkyl
  • X, Y, and Z are hydrogen
  • R3, R4, and R5 are absent
  • W is NRe
  • Ri and R2 are alkyl
  • X, Y, and Z are hydrogen
  • R3, R4, and R5 are absent
  • W is NRe
  • Rs is hydrogen
  • R9 is hydrogen.
  • Ri and R2 are alkyl
  • X, Y, and Z are hydrogen
  • R3, R4, and R5 are absent
  • W is NRe
  • Ri and R2 are alkyl
  • X, Y, and Z are hydrogen
  • R3, R4, and R5 are absent
  • W is NRe
  • Rs is hydrogen
  • R9 is hydrogen.
  • Ri and R2 are alkyl
  • X, Y, and Z are hydrogen
  • R3, R4, and R5 are absent
  • W is NRe
  • Ri and R2 are alkyl
  • X, Y, and Z are hydrogen
  • R3, R4, and R5 are absent
  • W is NRe
  • Rs is hydrogen
  • R9 is hydrogen.
  • Ri and R2 are alkyl
  • X, Y, and Z are hydrogen
  • R3, R4, and R5 are absent
  • W is NRe
  • Ri and R2 are alkyl
  • X, Y, and Z are hydrogen
  • R3, R4, and R5 are absent
  • W is NRe
  • Rs is hydrogen
  • R9 is hydrogen
  • Ri and R2 are alkyl
  • Y and Z are hydrogen
  • X is -O-
  • R3 is hydrogen
  • R4 and R5 are absent
  • W is NRe
  • Ri and R2 are alkyl
  • Y and Z are hydrogen
  • X is -O-
  • R3 is hydrogen
  • R4 and Rs are absent
  • W is NRe
  • Rs is hydrogen
  • R9 is hydrogen.
  • Ri and R2 are alkyl
  • X and Y are hydrogen
  • Z is -O-
  • Rs is hydrogen
  • R3 and R4 are absent
  • W is NRe
  • Ri and R2 are alkyl
  • X and Y are hydrogen
  • Z is -O-
  • Rs is hydrogen
  • R3 and R4 are absent
  • W is NRe
  • Rs is hydrogen
  • R9 is hydrogen.
  • Ri and R2 are alkyl
  • X and Z are hydrogen
  • Y is -O-
  • R4 is hydrogen
  • R3 and Rs are absent
  • W is NRe
  • W is NRe
  • Ri and R2 are alkyl
  • X and Z are hydrogen
  • Y is -O-
  • R4 is hydrogen
  • R3 and Rs are absent
  • W is NRe
  • Rs is hydrogen
  • R9 is hydrogen.
  • Ri and R2 are alkyl
  • Y and Z are hydrogen
  • X is -O-
  • R3 is hydrogen
  • R4 and Rs are absent
  • W is NRe
  • Ri and R2 are alkyl
  • Y and Z are hydrogen
  • X is -O-
  • R3 is hydrogen
  • R4 and Rs are absent
  • W is NRe
  • Rs is hydrogen
  • R9 is hydrogen.
  • Ri and R2 are alkyl
  • X and Y are hydrogen
  • Z is -O-
  • Rs is hydrogen
  • R3 and R4 are absent
  • W is NRe
  • Ri and R2 are alkyl
  • X and Y are hydrogen
  • Z is -O-
  • Rs is hydrogen
  • R3 and R4 are absent
  • W is NRe
  • Rs is hydrogen
  • R9 is hydrogen.
  • the present disclosure provides a compound of Formula I or pharmaceutically acceptable salts thereof selected from Table 1.
  • Ri and R2 are each independently hydrogen, alkyl, cycloalkyl, or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring;
  • X, Y and Z are each independently hydrogen, halogen, -O-, -S-, -NR7-, or -CH2-;
  • W is oxygen, sulfur or NRe
  • R 7 is hydrogen or alkyl
  • RA, RB, and Re are each independently hydrogen, alkyl, heteroalkyl, cycloalkyl, alkoxy, hemiacetal, ketal, or an amino acid; and m is an integer from 1-4.
  • the present disclosure provides compounds having the structure of Formula Ila: or a pharmaceutically acceptable salt thereof, wherein:
  • Ri and R2 are methyl
  • X, Y, and Z are each either absent or -O-;
  • R3, R4, and R5 are each independently absent, hydrogen, or C1-C3 alkyl, wherein when R3 is present X is -O-, when R4 is present Y is -O-, and when R5 is present Z is - O-;
  • Re is hydrogen or C1-C3 alkyl, wherein at least one of R3, R4, and R5 are present and non-hydrogen, and wherein when Re is H, at least one of XR3 and ZRs are -O-(Ci-C3 alkyl).
  • Ri and R2 are each independently alkyl, cycloalkyl, or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring. In embodiments, Ri and R2 are each independently hydrogen, cycloalkyl, or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring. In embodiments, Ri and R2 are each independently hydrogen, alkyl, or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring. In embodiments, Ri and R2 are each independently hydrogen, alkyl, or cycloalkyl.
  • Ri and R2 are each independently hydrogen or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring. In embodiments, Ri and R2 are each independently cycloalkyl or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring. In embodiments, Ri and R2 are each independently alkyl or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring. In embodiments, Ri and R2 are each independently alkyl or cycloalkyl. In embodiments, Ri and R2 are each independently hydrogen or cycloalkyl. In embodiments, Ri and R2 are each independently hydrogen or alkyl.
  • Ri and R2 are each alkyl. In embodiments, Ri and R2 are each hydrogen. In embodiments, one of Ri and R2 is hydrogen and one of Ri and R2 is alkyl.
  • Ri and R2 together with the atoms to which they are attached form a heterocyclic ring.
  • the heterocyclic ring is a monocyclic, bicyclic, tricyclic, or tetracyclic ring.
  • the heterocyclic ring is a monocyclic ring.
  • the heterocyclic ring is a bicyclic ring.
  • the heterocyclic ring is a tricyclic ring.
  • the heterocyclic ring is a tetracyclic ring.
  • X, Y and Z are each independently halogen, -O-, -S-, -NR?-,or - CH2-. In embodiments, X, Y and Z are each independently hydrogen, -O-, -S-, -NR7-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, halogen, -S-, - NR7-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, halogen, -O-, -NR7-, or -CH2-.
  • X, Y and Z are each independently hydrogen, halogen, -O-, -S-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, halogen, -O-, -S-, or -NR7-.
  • X, Y and Z are each independently -O-, -S-, -NR7-, or -CH2-. In embodiments, X, Y and Z are each independently halogen, -S-, -NR7-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, halogen, -O-, -NR7-, or - CH2-. In embodiments, halogen, -O-, -S-, or -CH2-. In embodiments, halogen, -O-, - S-, or -NR7-.
  • X, Y and Z are each independently hydrogen, -S-, -NR7-, or -CH2- In embodiments, X, Y and Z are each independently hydrogen, -O-, -NR7-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, -O-, -S-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, -O-, -S-, or -NR7-. In embodiments, X, Y and Z are each independently hydrogen, halogen, -NR7-, or -CH2-.
  • X, Y and Z are each independently hydrogen, halogen, -S-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, halogen, -S-, or -NR7-. In embodiments, X, Y and Z are each independently hydrogen, halogen, -O-, or -S-.
  • X, Y and Z are each independently -S-, -NR7-, or -CH2-. In embodiments, X, Y and Z are each independently -O-, -NR7-, or-CH2- In embodiments,
  • X, Y and Z are each independently -O-, -S-, or -CH2-. In embodiments, X, Y and Z are each independently -O-, -S-, or -NR7-. In embodiments, X, Y and Z are each independently hydrogen, -NR7-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, -S-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen -S-, or -NR7-. In embodiments, X, Y and Z are each independently hydrogen, halogen, or -CH2-. X, Y and Z are each independently hydrogen, halogen, or -NR7-. In embodiments, X, Y and Z are each independently hydrogen, halogen, or -O-.
  • X, Y and Z are each independently hydrogen or halogen. In embodiments, X, Y, and Z are each independently hydrogen or -O-. In embodiments, X,
  • Y, and Z are each independently hydrogen or -S-. In embodiments, X, Y, and Z are each independently hydrogen or -NR7-. In embodiments, X, Y, and Z are each independently hydrogen or -CH2-.
  • X, Y and Z are each independently halogen or -O-. In embodiments,
  • X, Y and Z are each independently halogen or -S-. In embodiments, X, Y and Z are each independently halogen or -NR7-. In embodiments, X, Y and Z are each independently halogen or -CH2-.
  • X, Y, and Z are each independently -O- or -S-. In embodiments, X,
  • Y, and Z are each independently -O- or -NR7-. In embodiments, Z, Y, and Z are each independently -O- or -CH2-. In embodiments, X, Y, and Z are each independently -S- or -NR7- In embodiments, Z, Y, and Z are each independently -S- or -CH2-. [0148] In embodiments, X is hydrogen. In embodiments, X is halogen. In embodiments, X is -O-. In embodiments, X is -S-. In embodiments, X is -NR7-. In embodiments, X is - CH 2 -.
  • Y is hydrogen. In embodiments, Y is halogen. In embodiments, Y is -O-. In embodiments, Y is -S-. In embodiments, Y is -NR7-. In embodiments, Y is - CH2-.
  • Y is hydrogen.
  • Z is halogen.
  • Z is -O-.
  • Z is -S-.
  • Z is -NR7-.
  • Z is - CH2-.
  • R3 and R4 are hydrogen and R5 is alkyl.
  • R3 and R5 are hydrogen and R4 is alkyl.
  • R4 and R5 are hydrogen and R3 is alkyl.
  • R3, R4, and R5 are each hydrogen.
  • R3 and R4 are hydrogen
  • R5 is hydrogen
  • X and Y are absent
  • Z is -O-.
  • R3 and R4 are hydrogen, R5 is alkyl, X and Y are absent, and Z is -O-
  • R3 and R5 are hydrogen, R4 is hydrogen, X and Z are absent, and Y is -O-.
  • R3 and R5 are hydrogen, R4 is alkyl, X and Z are absent, and Y is -O-
  • R4 and R5 are hydrogen, R3 is hydrogen, Y and Z are absent, and X is -O-.
  • R4 and R5 are hydrogen, R3 is alkyl, Y and Z are absent, and X is -O-
  • R7 is hydrogen. In embodiments, R7 is alkyl. In embodiments, R7 is a Ci-Ce alkyl. In embodiments, R7 is a Ci alkyl. In embodiments, R7 is a C2 alkyl. In embodiments, R7 is a C3 alkyl.
  • RA, RB, and R c are each independently alkyl, heteroalkyl, cycloalkyl, alkoxy, hemiacetal, ketal, or an amino acid. In embodiments, RA, RB, and R c are each independently hydrogen, heteroalkyl, cycloalkyl, alkoxy, hemiacetal, ketal, or an amino acid. In embodiments, RA, RB, and Rc are each independently hydrogen, alkyl, cycloalkyl, alkoxy, hemiacetal, ketal, or an amino acid.
  • RA, RB, and R c are each independently hydrogen, alkyl, heteroalkyl, alkoxy, hemiacetal, ketal, or an amino acid. In embodiments, RA, RB, and R c are each independently hydrogen, alkyl, heteroalkyl, cycloalkyl, hemiacetal, ketal, or an amino acid. In embodiments, RA, RB, and R c are each independently hydrogen, alkyl, heteroalkyl, cycloalkyl, alkoxy, ketal, or an amino acid.
  • RA, RB, and R c are each independently hydrogen, alkyl, heteroalkyl, cycloalkyl, alkoxy, hemiacetal, or an amino acid. In embodiments, RA, RB, and Rc are each independently hydrogen, alkyl, heteroalkyl, cycloalkyl, alkoxy, hemiacetal, or ketal. [0181] In embodiments, RA, RB, and Re are each hydrogen. In embodiments, RA and R c are each hydrogen. In embodiments, RA and RB are each hydrogen. In embodiments, RB and Re are each hydrogen.
  • RA, RB, and R c are each alkyl.
  • RA and Re are each alkyl.
  • RA and RB are each alkyl.
  • RB and R c are each alkyl.
  • RA is hydrogen.
  • RB is hydrogen.
  • Rc is hydrogen.
  • RA is hydrogen and RB is alkyl. In embodiments, RA is alkyl and RB is hydrogen.
  • Rc is hydrogen. In embodiments Rc is alkyl.
  • m is an integer from 1-4. In embodiments, m is 1. In embodiments, m is 2. In embodiments, m is 3. In embodiments, m is 4.
  • Ri and R2 are alkyl
  • Y and Z are hydrogen
  • X is -O-
  • R3 is alkyl
  • R4 and Rs are absent.
  • Ri and R2 are alkyl
  • Y and Z are hydrogen
  • X is -O-
  • R3 is alkyl
  • R4 and R5 are absent
  • Rc is hydrogen
  • Ri and R2 are alkyl
  • Y and Z are hydrogen
  • X is -O-
  • R3 is alkyl
  • R4 and R5 are absent
  • Rc is alkyl
  • Ri and R2 are alkyl
  • X and Z are hydrogen
  • Y is -O-
  • R4 is alkyl
  • R3 and Rs are absent.
  • Ri and R2 are alkyl
  • X and Z are hydrogen
  • Y is -O-
  • R4 is alkyl
  • R3 and R5 are absent
  • Rc is hydrogen
  • Ri and R2 are alkyl
  • X and Z are hydrogen
  • Y is -O-
  • R4 is alkyl
  • R3 and R5 are absent
  • Rc is alkyl
  • Ri and R2 are alkyl
  • X and Y are hydrogen
  • Z is -O-
  • R5 is alkyl
  • R3 and R4 are absent.
  • Ri and R2 are alkyl, X and Y are hydrogen, Z is -O-, R5 is alkyl, R3 and R4 are absent, and Rc is hydrogen.
  • Ri and R2 are alkyl, X and Y are hydrogen, Z is -O-, R5 is alkyl, R3 and R4 are absent, and Rc is alkyl.
  • Ri and R2 are alkyl
  • Y and Z are hydrogen
  • X is -O-
  • R3 is hydrogen
  • R4 and Rs are absent.
  • Ri and R2 are alkyl
  • Y and Z are hydrogen
  • X is -O-
  • R3 is hydrogen
  • R4 and Rs are absent
  • Rc is hydrogen
  • Ri and R2 are alkyl
  • Y and Z are hydrogen
  • X is -O-
  • R3 is hydrogen
  • R4 and Rs are absent
  • Rc is alkyl
  • Ri and R2 are alkyl
  • X and Z are hydrogen
  • Y is -O-
  • R4 is hydrogen
  • R3 and Rs are absent.
  • Ri and R2 are alkyl
  • X and Z are hydrogen
  • Y is -O-
  • R4 is hydrogen
  • R3 and Rs are absent
  • Rc is hydrogen
  • Ri and R2 are alkyl
  • X and Z are hydrogen
  • Y is -O-
  • R4 is hydrogen
  • R3 and Rs are absent
  • Rc is alkyl
  • Ri and R2 are alkyl
  • X and Y are hydrogen
  • Z is -O-
  • Rs is hydrogen
  • R3 and R4 are absent.
  • Ri and R2 are alkyl
  • X and Y are hydrogen
  • Z is -O-
  • Rs is hydrogen
  • R3 and R4 are absent
  • Rc is hydrogen
  • Ri and R2 are alkyl
  • X and Y are hydrogen
  • Z is -O-
  • Rs is hydrogen
  • R3 and R4 are absent
  • Rc is alkyl
  • the present disclosure provides a compound of Formula II or pharmaceutically acceptable salts thereof selected from Table 2.
  • Ri and R2 are each independently hydrogen, alkyl, cycloalkyl, or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring;
  • X, Y and Z are each independently hydrogen, halogen, -O-, -S-, -NR7-, or -CH2-;
  • W is oxygen, sulfur or NRe
  • R 7 is hydrogen or alkyl
  • R 9 is hydrogen, alkyl, or halogen
  • RA, RB, and Re are each independently hydrogen, alkyl, heteroalkyl, cycloalkyl, alkoxy, hemiacetal, ketal, or an amino acid;
  • A- is a pharmaceutically acceptable anion; and m is an integer from 1-4.
  • Ri and R2 are each independently hydrogen, alkyl, cycloalkyl, or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring;
  • X, Y and Z are each independently hydrogen, halogen, -O-, -S-, -NR 7 -, or -CH2-;
  • R3, R4, and R5 are each independently absent, hydrogen, or alkyl
  • W is oxygen, sulfur or NRe
  • Re is absent, hydrogen, or alkyl
  • R7 is hydrogen or alkyl
  • Ro is hydrogen, alkyl, or halogen
  • RA, RB, and Re are each independently hydrogen, alkyl, heteroalkyl, cycloalkyl, alkoxy, hemiacetal, ketal, or an amino acid;
  • A- is a pharmaceutically acceptable anion; and m is an integer from 1-4.
  • the present disclosure provides compounds having the structure of
  • Ri and R 2 are methyl
  • X, Y, and Z are each either absent or -O-;
  • R3, R4, and R5 are each independently absent, hydrogen, or C1-C3 alkyl, wherein when R3 is present X is -O-, when R4 is present Y is -O-, and when R5 is present Z is - O-;
  • R7 is hydrogen or alkyl
  • Ri and R2 are each independently alkyl, cycloalkyl, or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring. In embodiments, Ri and R2 are each independently hydrogen, cycloalkyl, or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring. In embodiments, Ri and R2 are each independently hydrogen, alkyl, or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring. In embodiments, Ri and R2 are each independently hydrogen, alkyl, or cycloalkyl.
  • Ri and R2 are each independently hydrogen or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring. In embodiments, Ri and R2 are each independently cycloalkyl or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring. In embodiments, Ri and R2 are each independently alkyl or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring. In embodiments, Ri and R2 are each independently alkyl or cycloalkyl. In embodiments, Ri and R2 are each independently hydrogen or cycloalkyl. In embodiments, Ri and R2 are each independently hydrogen or alkyl.
  • Ri and R2 are each alkyl. In embodiments, Ri and R2 are each hydrogen. In embodiments, one of Ri and R2 is hydrogen and one of Ri and R2 is alkyl.
  • Ri and R2 together with the atoms to which they are attached form a heterocyclic ring.
  • the heterocyclic ring is a monocyclic, bicyclic, tricyclic, or tetracyclic ring.
  • the heterocyclic ring is a monocyclic ring.
  • the heterocyclic ring is a bicyclic ring.
  • the heterocyclic ring is a tricyclic ring.
  • the heterocyclic ring is a tetracyclic ring.
  • X, Y and Z are each independently halogen, -O-, -S-, -NR?-,or - CH2-. In embodiments, X, Y and Z are each independently hydrogen, -O-, -S-, -NR7-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, halogen, -S-, - NR7-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, halogen, -O-, -NR7-, or -CH2-.
  • X, Y and Z are each independently hydrogen, halogen, -O-, -S-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, halogen, -O-, -S-, or -NR7-. [0214] In embodiments, X, Y and Z are each independently -O-, -S-, -NR7-, or -CH2-. In embodiments, X, Y and Z are each independently halogen, -S-, -NR7-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, halogen, -O-, -NR7-, or - CH2-. In embodiments, halogen, -O-, -S-, or -CH2-. In embodiments, halogen, -O-, - S-, or -NR7-.
  • X, Y and Z are each independently hydrogen, -S-, -NR7-, or -CH2- .
  • X, Y and Z are each independently hydrogen, -O-, -NR7-, or -CH2-.
  • X, Y and Z are each independently hydrogen, -O-, -S-, or -CH2-.
  • X, Y and Z are each independently hydrogen, -O-, -S-, or -NR7-.
  • X, Y and Z are each independently hydrogen, halogen, -NR7-, or -CH2-.
  • X, Y and Z are each independently hydrogen, halogen, -S-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, halogen, -S-, or -NR7-. In embodiments, X, Y and Z are each independently hydrogen, halogen, -O-, or -S-.
  • X, Y and Z are each independently -S-, -NR7-, or -CH2-. In embodiments, X, Y and Z are each independently -O-, -NR7-, or-CH2- In embodiments,
  • X, Y and Z are each independently -O-, -S-, or -CH2-. In embodiments, X, Y and Z are each independently -O-, -S-, or -NR7-. In embodiments, X, Y and Z are each independently hydrogen, -NR7-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, -S-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen -S-, or -NR7-. In embodiments, X, Y and Z are each independently hydrogen, halogen, or -CH2-. X, Y and Z are each independently hydrogen, halogen, or -NR7-. In embodiments, X, Y and Z are each independently hydrogen, halogen, or -O-.
  • X, Y and Z are each independently hydrogen or halogen. In embodiments, X, Y, and Z are each independently hydrogen or -O-. In embodiments, X,
  • Y, and Z are each independently hydrogen or -S-. In embodiments, X, Y, and Z are each independently hydrogen or -NR7-. In embodiments, X, Y, and Z are each independently hydrogen or -CH2-.
  • X, Y and Z are each independently halogen or -O-. In embodiments, X, Y and Z are each independently halogen or -S-. In embodiments, X, Y and Z are each independently halogen or -NR7-. In embodiments, X, Y and Z are each independently halogen or -CH2-. [0219] In embodiments, X, Y, and Z are each independently -O- or -S-. In embodiments, X, Y, and Z are each independently -O- or -NR7-. In embodiments, Z, Y, and Z are each independently -O- or -CH2-. In embodiments, X, Y, and Z are each independently -S- or -NR7-. In embodiments, Z, Y, and Z are each independently -S- or -CH2-. In embodiments, X, Y, and Z are each independently -S- or -NR7-. In embodiments, Z, Y, and
  • X is hydrogen. In embodiments, X is halogen. In embodiments, X is -O-. In embodiments, X is -S-. In embodiments, X is -NR7-. In embodiments, X is - CH2-.
  • Y is hydrogen. In embodiments, Y is halogen. In embodiments, Y is -O-. In embodiments, Y is -S-. In embodiments, Y is -NR7-. In embodiments, Y is - CH2-.
  • Y is hydrogen.
  • Z is halogen.
  • Z is -O-.
  • Z is -S-.
  • Z is -NR7-.
  • Z is - CH2-.
  • R3 and R4 are hydrogen and Rs is alkyl.
  • R3 and Rs are hydrogen and R4 is alkyl.
  • R4 and Rs are hydrogen and R3 is alkyl.
  • R3, R4, and Rs are each hydrogen.
  • R3 and R4 are hydrogen, Rs is hydrogen, X and Y are absent, and Z is
  • R3 and R4 are hydrogen, R5 is alkyl, X and Y are absent, and Z is -O-
  • R3 and R5 are hydrogen, R4 is hydrogen, X and Z are absent, and Y is -O-.
  • R3 and R5 are hydrogen, R4 is alkyl, X and Z are absent, and Y is -O-
  • R4 and R5 are hydrogen, R3 is hydrogen, Y and Z are absent, and X is -O-.
  • R4 and R5 are hydrogen, R3 is alkyl, Y and Z are absent, and X is -O-
  • W is oxygen or sulfur. In embodiments, W is oxygen or NRe. In embodiments, W is sulfur or NRe. In embodiments, W is oxygen. In embodiments, W is sulfur. In embodiments, W is NRe.
  • Rio is hydrogen.
  • Rio is alkyl.
  • R 7 is hydrogen. In embodiments, R 7 is alkyl. In embodiments, R 7 is a Ci-Ce alkyl. In embodiments, R 7 is a Ci alkyl. In embodiments, R 7 is a C 2 alkyl. In embodiments, R 7 is a C3 alkyl.
  • RA, RB, and R c are each independently alkyl, heteroalkyl, cycloalkyl, alkoxy, hemiacetal, ketal, or an amino acid. In embodiments, RA, RB, and R c are each independently hydrogen, heteroalkyl, cycloalkyl, alkoxy, hemiacetal, ketal, or an amino acid. In embodiments, RA, RB, and Rc are each independently hydrogen, alkyl, cycloalkyl, alkoxy, hemiacetal, ketal, or an amino acid.
  • RA, RB, and R c are each independently hydrogen, alkyl, heteroalkyl, alkoxy, hemiacetal, ketal, or an amino acid. In embodiments, RA, RB, and R c are each independently hydrogen, alkyl, heteroalkyl, cycloalkyl, hemiacetal, ketal, or an amino acid. In embodiments, RA, RB, and R c are each independently hydrogen, alkyl, heteroalkyl, cycloalkyl, alkoxy, ketal, or an amino acid.
  • RA, RB, and R c are each independently hydrogen, alkyl, heteroalkyl, cycloalkyl, alkoxy, hemiacetal, or an amino acid. In embodiments, RA, RB, and Rc are each independently hydrogen, alkyl, heteroalkyl, cycloalkyl, alkoxy, hemiacetal, or ketal.
  • RA, RB, and Rc are each hydrogen. In embodiments, RA and R c are each hydrogen. In embodiments, RA and RB are each hydrogen. In embodiments, RB and Rc are each hydrogen.
  • RA, RB, and R c are each alkyl. In embodiments, RA and Rc are each alkyl. In embodiments, RA and RB are each alkyl. In embodiments, RB and R c are each alkyl. [0256] In embodiments, RA is hydrogen. In embodiments, RB is hydrogen. In embodiments, Re is hydrogen.
  • RA is hydrogen and RB is alkyl. In embodiments, RA is alkyl and RB is hydrogen.
  • Rc is hydrogen. In embodiments Rc is alkyl.
  • Rs is hydrogen. In embodiments, Rs is alkyl. In embodiments, Rs is Ci-Ce alkyl. In embodiments, Rs is Ci alkyl. In embodiments, Rs is C2 alkyl. In embodiments, Rs is C3 alkyl. In embodiments, Rs is a C4 alkyl. In embodiments, Rs is C5 alkyl. In embodiments, Rs is Ce alkyl.
  • R9 is hydrogen, alkyl, or halogen. In embodiments, R9 is hydrogen. In embodiments, R9 is alkyl. In embodiments, R9 is halogen.
  • m is an integer from 1-4. In embodiments, m is 1. In embodiments, m is 2. In embodiments, m is 3. In embodiments, m is 4.
  • Ri and R2 are alkyl
  • X and Z are hydrogen
  • Y is -O-
  • R4 is alkyl
  • R3 and R5 are absent
  • Ri and R2 are alkyl
  • X and Z are hydrogen
  • Y is -O-
  • R4 is alkyl
  • R3 and R5 are absent
  • W is NRe
  • Re is hydrogen
  • Rs is hydrogen
  • R9 is hydrogen
  • Ri and R2 are alkyl
  • Y and Z are hydrogen
  • X is -O-
  • R3 is alkyl
  • R4 and R5 are absent
  • Ri and R2 are alkyl
  • Y and Z are hydrogen
  • X is -O-
  • R3 is alkyl
  • R4 and R5 are absent
  • W is NRe
  • Re is hydrogen
  • Rs is hydrogen
  • R9 is hydrogen
  • Ri and R2 are alkyl
  • X and Y are hydrogen
  • Z is -O-
  • R5 is alkyl
  • R3 and R4 are absent
  • Ri and R2 are alkyl
  • X and Y are hydrogen
  • Z is -O-
  • R5 is alkyl
  • R3 and R4 are absent
  • W is NRe
  • Re is hydrogen
  • Rs is hydrogen
  • R9 is hydrogen
  • Ri and R2 are alkyl
  • X and Z are hydrogen
  • Y is -O-
  • R4 is hydrogen
  • R3 and R5 are absent
  • Ri and R2 are alkyl
  • X and Z are hydrogen
  • Y is -O-
  • R4 is hydrogen
  • R3 and R5 are absent
  • W is NRe
  • Re is hydrogen
  • Rs is hydrogen
  • R9 is hydrogen
  • Ri and R2 are alkyl
  • Y and Z are hydrogen
  • X is -O-
  • R3 is hydrogen
  • R4 and R5 are absent
  • Ri and R2 are alkyl
  • Y and Z are hydrogen
  • X is -O-
  • R3 is hydrogen
  • R4 and R5 are absent
  • W is NRe
  • Re is hydrogen
  • Rs is hydrogen
  • R9 is hydrogen
  • Ri and R2 are alkyl
  • X and Y are hydrogen
  • Z is -O-
  • R5 is hydrogen
  • R3 and R4 are absent
  • Ri and R2 are alkyl
  • X and Y are hydrogen
  • Z is -O-
  • R5 is hydrogen
  • R3 and R4 are absent
  • W is NRe
  • Re is hydrogen
  • Rs is hydrogen
  • R9 is hydrogen
  • Ri and R2 are alkyl
  • X, Y, and Z are hydrogen
  • R3, R4, and R5 are absent
  • the present disclosure provides a compound of Formula III or pharmaceutically acceptable salts thereof selected from Table 3.
  • Ri and R2 are each independently hydrogen, alkyl, cycloalkyl, or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring;
  • X, Y and Z are each independently hydrogen, halogen, -O-, -S-, -NR7-, or -CH2-;
  • R 7 is hydrogen or alkyl
  • R 9 is hydrogen, alkyl, or halogen
  • RA and RB are each independently hydrogen, alkyl, heteroalkyl, cycloalkyl, alkoxy, hemiacetal, ketal, or am amino acid; m is an integer from 1-4; and
  • A- is a pharmaceutically acceptable anion.
  • Ri and R2 are each independently hydrogen, alkyl, cycloalkyl, or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring;
  • X, Y and Z are each independently hydrogen, halogen, -O-, -S-, -NR 7 -, or -CH 2 -;
  • R 7 is hydrogen or alkyl
  • Ro is hydrogen, alkyl, or halogen
  • RA and RB are each independently hydrogen, alkyl, heteroalkyl, cycloalkyl, alkoxy, hemiacetal, ketal, or am amino acid; m is an integer from 1-4; and
  • A- is a pharmaceutically acceptable anion.
  • the present disclosure provides for compounds of Formula (IVa): or a pharmaceutically acceptable salt thereof, wherein:
  • Ri and R 2 are each methyl
  • X, Y, and Z are each either absent or -O-;
  • Ri and R2 are each independently alkyl, cycloalkyl, or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring. In embodiments, Ri and R2 are each independently hydrogen, cycloalkyl, or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring. In embodiments, Ri and R2 are each independently hydrogen, alkyl, or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring. In embodiments, Ri and R2 are each independently hydrogen, alkyl, or cycloalkyl.
  • Ri and R2 are each independently hydrogen or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring. In embodiments, Ri and R2 are each independently cycloalkyl or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring. In embodiments, Ri and R2 are each independently alkyl or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring. In embodiments, Ri and R2 are each independently alkyl or cycloalkyl. In embodiments, Ri and R2 are each independently hydrogen or cycloalkyl. In embodiments, Ri and R2 are each independently hydrogen or alkyl.
  • Ri and R2 are each alkyl. In embodiments, Ri and R2 are each hydrogen. In embodiments, one of Ri and R2 is hydrogen and one of Ri and R2 is alkyl.
  • Ri and R2 together with the atoms to which they are attached form a heterocyclic ring.
  • the heterocyclic ring is a monocyclic, bicyclic, tricyclic, or tetracyclic ring.
  • the heterocyclic ring is a monocyclic ring.
  • the heterocyclic ring is a bicyclic ring.
  • the heterocyclic ring is a tricyclic ring.
  • the heterocyclic ring is a tetracyclic ring.
  • X, Y and Z are each independently halogen, -O-, -S-, -NR?-,or - CH2-. In embodiments, X, Y and Z are each independently hydrogen, -O-, -S-, -NR7-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, halogen, -S-, - NR7-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, halogen, -O-, -NR7-, or -CH2-.
  • X, Y and Z are each independently hydrogen, halogen, -O-, -S-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, halogen, -O-, -S-, or -NR7-. [0293] In embodiments, X, Y and Z are each independently -O-, -S-, -NR7-, or -CH2-. In embodiments, X, Y and Z are each independently halogen, -S-, -NR7-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, halogen, -O-, -NR7-, or - CH2-. In embodiments, halogen, -O-, -S-, or -CH2-. In embodiments, halogen, -O-, - S-, or -NR7-.
  • X, Y and Z are each independently hydrogen, -S-, -NR7-, or -CH2- . In embodiments, X, Y and Z are each independently hydrogen, -O-, -NR7-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, -O-, -S-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, -O-, -S-, or -NR7-. In embodiments, X, Y and Z are each independently hydrogen, halogen, -NR7-, or -CH2-.
  • X, Y and Z are each independently hydrogen, halogen, -S-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, halogen, -S-, or -NR7-. In embodiments, X, Y and Z are each independently hydrogen, halogen, -O-, or -S-.
  • X, Y and Z are each independently -S-, -NR7-, or -CH2-. In embodiments, X, Y and Z are each independently -O-, -NR7-, or-CH2- In embodiments,
  • X, Y and Z are each independently -O-, -S-, or -CH2-. In embodiments, X, Y and Z are each independently -O-, -S-, or -NR7-. In embodiments, X, Y and Z are each independently hydrogen, -NR7-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen, -S-, or -CH2-. In embodiments, X, Y and Z are each independently hydrogen -S-, or -NR7-. In embodiments, X, Y and Z are each independently hydrogen, halogen, or -CH2-. X, Y and Z are each independently hydrogen, halogen, or -NR7-. In embodiments, X, Y and Z are each independently hydrogen, halogen, or -O-.
  • X, Y and Z are each independently hydrogen or halogen. In embodiments, X, Y, and Z are each independently hydrogen or -O-. In embodiments, X,
  • Y, and Z are each independently hydrogen or -S-. In embodiments, X, Y, and Z are each independently hydrogen or -NR7-. In embodiments, X, Y, and Z are each independently hydrogen or -CH2-.
  • X, Y and Z are each independently halogen or -O-. In embodiments, X, Y and Z are each independently halogen or -S-. In embodiments, X, Y and Z are each independently halogen or -NR7-. In embodiments, X, Y and Z are each independently halogen or -CH2-. [0298] In embodiments, X, Y, and Z are each independently -O- or -S-. In embodiments, X, Y, and Z are each independently -O- or -NR7-. In embodiments, Z, Y, and Z are each independently -O- or -CH2-. In embodiments, X, Y, and Z are each independently -S- or -NR7-. In embodiments, Z, Y, and Z are each independently -S- or -CH2-. In embodiments, X, Y, and Z are each independently -S- or -NR7-. In embodiments, Z, Y, and
  • X is hydrogen. In embodiments, X is halogen. In embodiments, X is -O-. In embodiments, X is -S-. In embodiments, X is -NR7-. In embodiments, X is - CH2-.
  • Y is hydrogen. In embodiments, Y is halogen. In embodiments, Y is -O-. In embodiments, Y is -S-. In embodiments, Y is -NR7-. In embodiments, Y is - CH2-.
  • Y is hydrogen.
  • Z is halogen.
  • Z is -O-.
  • Z is -S-.
  • Z is -NR7-.
  • Z is - CH2-.
  • R3 and R4 are hydrogen and Rs is alkyl.
  • R3 and Rs are hydrogen and R4 is alkyl.
  • R4 and Rs are hydrogen and R3 is alkyl.
  • R3, R4, and Rs are each hydrogen.
  • R3 and R4 are hydrogen, Rs is hydrogen, X and Y are absent, and Z is
  • R3 and R4 are hydrogen, R5 is alkyl, X and Y are absent, and Z is -O-
  • R3 and R5 are hydrogen, R4 is hydrogen, X and Z are absent, and Y is -O-.
  • R3 and R5 are hydrogen, R4 is alkyl, X and Z are absent, and Y is -O-
  • R4 and R5 are hydrogen, R3 is hydrogen, Y and Z are absent, and X is -O-.
  • R4 and R5 are hydrogen, R3 is alkyl, Y and Z are absent, and X is -O-
  • W is oxygen or sulfur. In embodiments, W is oxygen or NRe. In embodiments, W is sulfur or NRe. In embodiments, W is oxygen. In embodiments, W is sulfur. In embodiments, W is NRe.
  • R 7 is hydrogen. In embodiments, R 7 is alkyl. In embodiments, R 7 is a Ci-Ce alkyl. In embodiments, R 7 is a Ci alkyl. In embodiments, R 7 is a C 2 alkyl. In embodiments, R 7 is a C3 alkyl.
  • RA, RB, and R c are each independently alkyl, heteroalkyl, cycloalkyl, alkoxy, hemiacetal, ketal, or an amino acid. In embodiments, RA, RB, and R c are each independently hydrogen, heteroalkyl, cycloalkyl, alkoxy, hemiacetal, ketal, or an amino acid. In embodiments, RA, RB, and Rc are each independently hydrogen, alkyl, cycloalkyl, alkoxy, hemiacetal, ketal, or an amino acid.
  • RA, RB, and R c are each independently hydrogen, alkyl, heteroalkyl, alkoxy, hemiacetal, ketal, or an amino acid. In embodiments, RA, RB, and R c are each independently hydrogen, alkyl, heteroalkyl, cycloalkyl, hemiacetal, ketal, or an amino acid. In embodiments, RA, RB, and R c are each independently hydrogen, alkyl, heteroalkyl, cycloalkyl, alkoxy, ketal, or an amino acid.
  • RA, RB, and R c are each independently hydrogen, alkyl, heteroalkyl, cycloalkyl, alkoxy, hemiacetal, or an amino acid. In embodiments, RA, RB, and Rc are each independently hydrogen, alkyl, heteroalkyl, cycloalkyl, alkoxy, hemiacetal, or ketal.
  • RA, RB, and Rc are each hydrogen. In embodiments, RA and R c are each hydrogen. In embodiments, RA and RB are each hydrogen. In embodiments, RB and Rc are each hydrogen. [0332] In embodiments, RA, RB, and R c are each alkyl. In embodiments, RA and Re are each alkyl. In embodiments, RA and RB are each alkyl. In embodiments, RB and R c are each alkyl.
  • RA is hydrogen.
  • RB is hydrogen.
  • Rc is hydrogen.
  • RA is hydrogen and RB is alkyl. In embodiments, RA is alkyl and RB is hydrogen.
  • Rc is hydrogen. In embodiments Rc is alkyl.
  • Rs is hydrogen. In embodiments, Rs is alkyl. In embodiments, Rs is Ci-Ce alkyl. In embodiments, Rs is Ci alkyl. In embodiments, Rs is C2 alkyl. In embodiments, Rs is C3 alkyl. In embodiments, Rs is a C4 alkyl. In embodiments, Rs is C5 alkyl. In embodiments, Rs is Ce alkyl.
  • R9 is hydrogen, alkyl, or halogen. In embodiments, R9 is hydrogen. In embodiments, R9 is alkyl. In embodiments, R9 is halogen.
  • m is an integer from 1-4. In embodiments, m is 1. In embodiments, m is 2. In embodiments, m is 3. In embodiments, m is 4.
  • Ri and R2 are alkyl
  • X and Z are hydrogen
  • Y is -O-
  • R4 is alkyl
  • R3 and Rs are absent
  • Ri and R2 are alkyl
  • X and Z are hydrogen
  • Y is -O-
  • R4 is alkyl
  • R3 and R5 are absent
  • Rs is hydrogen
  • R9 is hydrogen
  • Ri and R2 are alkyl
  • Y and Z are hydrogen
  • X is -O-
  • R3 is alkyl
  • R4 and R5 are absent
  • Ri and R2 are alkyl
  • Y and Z are hydrogen
  • X is -O-
  • R3 is alkyl
  • R4 and R5 are absent
  • Rs is hydrogen
  • R9 is hydrogen
  • Ri and R2 are alkyl
  • X and Y are hydrogen
  • Z is -O-
  • R5 is alkyl
  • R3 and R4 are absent
  • Ri and R2 are alkyl
  • X and Y are hydrogen
  • Z is -O-
  • R5 is alkyl
  • R3 and R4 are absent
  • Rs is hydrogen
  • R9 is hydrogen
  • Ri and R2 are alkyl
  • X and Z are hydrogen
  • Y is -O-
  • R4 is hydrogen
  • R3 and R5 are absent
  • Ri and R2 are alkyl
  • X and Z are hydrogen
  • Y is -O-
  • R4 is hydrogen
  • R3 and R5 are absent
  • Rs is hydrogen
  • R9 is hydrogen
  • Ri and R2 are alkyl
  • Y and Z are hydrogen
  • X is -O-
  • R3 is hydrogen
  • R4 and R5 are absent
  • Ri and R2 are alkyl
  • Y and Z are hydrogen
  • X is -O-
  • R3 is hydrogen
  • R4 and R5 are absent
  • Rs is hydrogen
  • R9 is hydrogen
  • Ri and R2 are alkyl
  • X and Y are hydrogen
  • Z is -O-
  • R5 is hydrogen
  • R3 and R4 are absent
  • Ri and R2 are alkyl
  • X and Z are hydrogen
  • R3 and R5 are absent
  • Y is -O-
  • Rio is hydrogen
  • Ri and R2 are alkyl
  • X and Z are hydrogen
  • R3 and R5 are absent
  • Y is -O-
  • RS is hydrogen
  • R9 is hydrogen
  • Rio is hydrogen.
  • Ri and R2 are alkyl
  • X and Y are hydrogen
  • R3 and R4 are absent
  • Z is -O-
  • Rio is hydrogen
  • Ri and R2 are alkyl
  • X and Y are hydrogen
  • R3 and R4 are absent
  • Z is -O-
  • RS is hydrogen
  • R9 is hydrogen
  • Rio is hydrogen.
  • Ri and R2 are alkyl
  • Y and Z are hydrogen
  • R4 and R5 are absent
  • X is -O-
  • Ri and R2 are alkyl
  • Y and Z are hydrogen
  • R4 and R5 are absent
  • X is -O-
  • RS is hydrogen
  • R9 is hydrogen
  • Rio is hydrogen.
  • the present disclosure provides a compound of Formula IV or pharmaceutically acceptable salts thereof selected from Table 4.
  • a pharmaceutical composition comprises a therapeutically effective amounts of one or more compounds of the present disclosure (e.g., a compound of Formula I, II, III, IV or Table 1-4) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
  • the pharmaceutically acceptable excipients and adjuvants are added to the composition or formulation for a variety of purposes.
  • a pharmaceutical composition comprising one or more compounds disclosed herein, or a pharmaceutically acceptable salt thereof, further comprise a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier includes a pharmaceutically acceptable excipient, binder, and/or diluent.
  • suitable pharmaceutically acceptable carriers include, but are not limited to, inert solid fillers or diluents and sterile aqueous or organic solutions.
  • suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylase, magnesium stearate, talc, silicic acid, viscous paraffin, and the like.
  • the compounds of the present disclosure can be formulated for administration by a variety of means including orally, parenterally, by inhalation spray, topically, or rectally in formulations containing pharmaceutically acceptable carriers, adjuvants and vehicles.
  • parenteral as used here includes subcutaneous, intravenous, intramuscular, and intraarterial injections with a variety of infusion techniques.
  • Intraarterial and intravenous injection as used herein includes administration through catheters.
  • the present disclosure provides methods of treating or preventing neurological disorders in a subject in need thereof, the methods comprising administering a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formula I, Formula II, Formula III, Formula IV, or Compounds of Tables 1-4), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof to the subject.
  • a compound disclosed herein e.g., a compound of Formula I, Formula II, Formula III, Formula IV, or Compounds of Tables 1-4
  • a pharmaceutically acceptable salt thereof e.g., a compound of Formula I, Formula II, Formula III, Formula IV, or Compounds of Tables 1-4
  • the neurological disorder is a mood disorder.
  • the mood disorder is clinical depression, postnatal depression or postpartum depression, perinatal depression, atypical depression, melancholic depression, psychotic major depression, cationic depression, seasonal affective disorder, dysthymia, double depression, depressive personality disorder, recurrent brief depression, major depressive disorder, minor depressive disorder, bipolar disorder or manic depressive disorder, depression caused by chronic medical conditions, treatment-resistant depression, refractory depression, suicidality, suicidal ideation, or suicidal behavior.
  • the method described herein provides therapeutic effect to a subject suffering from depression (e.g., moderate or severe depression).
  • the mood disorder is associated with neuroendocrine diseases and disorders, neurodegenerative diseases and disorders (e.g., epilepsy), movement disorders, tremor (e.g., Parkinson's Disease), or women's health disorders or conditions.
  • the mood disorder is depression.
  • the mood disorder is treatment-resistant depression or major depressive disorder.
  • the mood disorder is major depressive disorder.
  • the mood disorder is treatment-resistant depression.
  • the present disclosure provides methods of treating or preventing PTSD, mood disorders, general anxiety disorder, addictive disorders, and/or drug dependence in a subject in need thereof, the methods comprising administering a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formula I, Formula II, Formula III, Formula IV, or Compounds of Tables 1-4), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof to the subject.
  • a compound disclosed herein e.g., a compound of Formula I, Formula II, Formula III, Formula IV, or Compounds of Tables 1-4
  • the present disclosure provides methods of treating or preventing PTSD in a subject in need thereof, the methods comprising administering a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formula I, Formula II, Formula III, Formula IV, or Compounds of Tables 1-4), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof to the subject.
  • a compound disclosed herein e.g., a compound of Formula I, Formula II, Formula III, Formula IV, or Compounds of Tables 1-4
  • a pharmaceutically acceptable salt thereof e.g., a compound of Formula I, Formula II, Formula III, Formula IV, or Compounds of Tables 1-4
  • the methods include treating PTSD through induction and maintenance therapy by administering a compound disclosed herein, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
  • the compounds of the present disclosure are used for induction and maintenance therapy to treat PTSD with an improved safety profile when compared to treatment with the entactogenic, oneirophrenic or psychedelic compound (e.g., dimethyltryptamine or related compound, psilocybin, or MDMA) alone.
  • the entactogenic, oneirophrenic or psychedelic compound e.g., dimethyltryptamine or related compound, psilocybin, or MDMA
  • the present disclosure provides methods of treating or preventing behavioral or mood disorders in a subject in need thereof, the methods comprising administering a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formula I, Formula II, Formula III, Formula IV, or Compounds of Tables 1-4), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof to the subject.
  • a compound disclosed herein e.g., a compound of Formula I, Formula II, Formula III, Formula IV, or Compounds of Tables 1-4
  • the behavioral or mood disorder includes anxiety, such as social anxiety in autistic subjects (e.g., autistic adults) and anxiety related to life-threatening illnesses.
  • the behavioral or mood disorder includes stress (where moderation thereof is measured, e.g., by effects on amygdala responses).
  • the anxiety disorder is panic disorder, obsessive-compulsive disorder, and/or general anxiety disorder.
  • the subject suffers from a lack of motivation, attention, lack of accuracy in memory recall, speed of response, perseveration, and/or cognitive engagement.
  • Further examples include depression (e.g., MDD or TRD), attention disorders, disorders of executive function and/or cognitive engagement, obsessive compulsive disorder, bipolar disorder, panic disorder, phobia, schizophrenia, psychopathy, antisocial personality disorder and/or neurocognitive disorders.
  • the present disclosure provides methods for treating an addictive disorder in a subject in need thereof, the methods comprising administering a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formula I, Formula II, Formula III, Formula IV, or Compounds of Tables 1-4), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof to the subject.
  • a compound disclosed herein e.g., a compound of Formula I, Formula II, Formula III, Formula IV, or Compounds of Tables 1-4
  • the addictive disorder is alcohol abuse, substance abuse, smoking, obesity, or mixtures thereof.
  • the disorder is an eating disorder (e.g., anorexia nervosa, bulimia, nervosa, binge eating disorder, etc.) or an auditory disorder.
  • the present disclosure provides methods for treating an impulsive disorder in a subject in need thereof, the methods comprising administering a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formula I, Formula II, Formula III, Formula IV, or Compounds of Tables 1-4), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof to the subject.
  • a compound disclosed herein e.g., a compound of Formula I, Formula II, Formula III, Formula IV, or Compounds of Tables 1-4
  • a pharmaceutically acceptable salt thereof e.g., a compound of Formula I, Formula II, Formula III, Formula IV, or Compounds of Tables 1-4
  • the impulsive disorder is attention deficit hyperactivity disorder (ADHD), attention deficit disorder (ADD), Tourette’s syndrome, autism, or combinations thereof.
  • the present disclosure provides methods for treating a compulsive disorder in a subject in need thereof, the methods comprising administering a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formula I, Formula II, Formula III, Formula IV, or Compounds of Tables 1-4), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof to the subject.
  • a compound disclosed herein e.g., a compound of Formula I, Formula II, Formula III, Formula IV, or Compounds of Tables 1-4
  • a pharmaceutically acceptable salt thereof e.g., a compound of Formula I, Formula II, Formula III, Formula IV, or Compounds of Tables 1-4
  • the compulsive disorder is obsessive compulsive disorder (OCD), gambling, aberrant sexual behavior, or combinations thereof.
  • the present disclosure provides methods for treating a personality disorder in a subject in need thereof, the methods comprising administering a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formula I, Formula II, Formula III, Formula IV, or Compounds of Tables 1-4), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
  • a compound disclosed herein e.g., a compound of Formula I, Formula II, Formula III, Formula IV, or Compounds of Tables 1-4
  • a pharmaceutically acceptable salt thereof e.g., a compound of Formula I, Formula II, Formula III, Formula IV, or Compounds of Tables 1-4
  • the personality disorder is conduct disorder, antisocial personality, aggressive behavior, or combinations thereof to the subject.
  • Embodiment 1 A compound of Formula I: or a pharmaceutically acceptable salt thereof; wherein,
  • Ri and R2 are each independently hydrogen, alkyl, cycloalkyl, or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring;
  • X, Y and Z are each independently hydrogen, halogen, -O-, -S-, -NR7-, or - CH 2 -;
  • W is oxygen, sulfur or NRe
  • R7 is hydrogen or alkyl
  • R 9 is hydrogen, alkyl, or halogen
  • Embodiment 2 A compound of Formula (la): or a pharmaceutically acceptable salt thereof, wherein:
  • Ri and R2 are each both are methyl
  • X, Y, and Z are each either absent or -O-;
  • Embodiment 3 The compound of embodiment 1 or embodiment 2, wherein X is hydrogen and R3 is absent.
  • Embodiment 4 The compound of embodiment 1 or embodiment 2, wherein Y is hydrogen and R4 is absent.
  • Embodiment 5 The compound of embodiment 1 or embodiment 2, wherein Z is hydrogen and Rs is absent.
  • Embodiment 6 The compound of embodiment 1 or embodiment 2, wherein X is -O- and R3 is alkyl.
  • Embodiment 7 The compound of embodiment 1 or embodiment 2, wherein Y is -O- and R4 is alkyl.
  • Embodiment 8 The compound of embodiment 1 or embodiment 2, wherein Z is -O- and Rs is alkyl.
  • Embodiment 9 The compound of embodiment 1 or embodiment 2, wherein X is -O- and R3 is hydrogen.
  • Embodiment 10 The compound of embodiment 1 or embodiment 2, wherein Y is -O- and R4 is hydrogen.
  • Embodiment 11 The compound of embodiment 1 or embodiment 2, wherein Z is -O- and Rs is hydrogen.
  • Embodiment 15 The compound of any one of embodiments 12 to 14, wherein RA and
  • RB are hydrogen.
  • Embodiment 16 The compound of any one of embodiments 12 to 15, wherein R? is hydrogen.
  • Embodiment 17 The compound of any of embodiments 1-16, wherein W is NRe.
  • Embodiment 19 The compound of embodiment 18, wherein RA and RB hydrogen.
  • Embodiment 21 The compound of embodiment 20, wherein Rc is hydrogen.
  • Embodiment 23 The compound of embodiment 22, wherein the alkyl is a Ci-Ce alkyl.
  • Embodiment 24 The compound of embodiment 23, wherein the alkyl is a methyl.
  • Embodiment 26 The compound of embodiment 25, wherein the alkyl is a Ci-Ce alkyl.
  • Embodiment 27 The compound of embodiment 26, wherein the alkyl is a methyl.
  • Embodiment 29 The compound of any one of embodiments 18 to 28, wherein R? is hydrogen.
  • Embodiment 30 The compound of any one of embodiments 1 to 29, wherein m is 1.
  • Embodiment 31 The compounds of any one of embodiments 1 to 30, wherein Ri and R2 are each independently hydrogen or alkyl.
  • Embodiment 32 The compounds of any one of embodiments 1 to 31, wherein Ri and R2 are alkyl.
  • Embodiment 33 The compound of embodiment 1, wherein the compound is:
  • Embodiment 34 The compound of embodiment 1, having the structure of Formula III:
  • RA and RB are each independently hydrogen, alkyl, heteroalkyl, cycloalkyl, alkoxy, hemiacetal, ketal, or am amino acid;
  • A' is a pharmaceutically acceptable anion.
  • Embodiment 35 A compound of embodiment 1, having the structure of Formula Illa: (Illa), or a pharmaceutically acceptable salt thereof, wherein:
  • Ri and R2 are methyl
  • X, Y, and Z are each either absent or -O-;
  • RA and RB are each independently hydrogen or methyl
  • R? is hydrogen or alkyl
  • Embodiment 37 The compound of embodiment 36, wherein RA and RB are hydrogen.
  • Embodiment 38 The compound of embodiment 36 or 37, wherein R7 is hydrogen.
  • Embodiment 39 The compound of embodiment 34 or 35, wherein Rw is -CHR7-O- aryl.
  • Embodiment 40 The compound of embodiment 39, wherein R7 is hydrogen.
  • Embodiment 41 The compound of any of embodiments 34 to 40, wherein the pharmaceutically acceptable salt is a sodium (Na + ) or an ammonium (NH ) salt.
  • Embodiment 42 The compound of any of embodiments 34 to 41, wherein X is hydrogen and R3 is absent.
  • Embodiment 43 The compound of any of embodiments 34 to 42, wherein Y is hydrogen and R4 is absent.
  • Embodiment 44 The compound of any of embodiments 34 to 43, wherein Z is hydrogen and Rs is absent.
  • Embodiment 45 The compound of any of embodiments 34 to 44, wherein X is -O- and
  • R3 is alkyl
  • Embodiment 46 The compound of any of embodiments 34 to 45, wherein Y is -O- and
  • R4 is alkyl
  • Embodiment 47 The compound of any of embodiments 34 to 46, wherein Z is -O- and
  • Embodiment 48 The compound of any of embodiments 34 to 47, wherein X is -O- and
  • R3 is hydrogen
  • Embodiment 49 The compound of any of embodiments 34 to 48, wherein Y is -O- and
  • R4 is hydrogen.
  • Embodiment 50 The compound of any of embodiments 34 to 49, wherein Z is -O- and Rs is hydrogen.
  • Embodiment 51 The compound of any of embodiments 34 to 50, wherein Ri and R2 are each independently hydrogen or alkyl.
  • Embodiment 52 The compounds of any one of embodiments 34 to 51, wherein Ri and R2 are alkyl (such as methyl).
  • Embodiment 53 The compound embodiment 34, wherein the compound is:
  • Embodiment 54 A compound of Formula IV: or a pharmaceutically acceptable salt thereof; wherein, Ri and R2 are each independently hydrogen, alkyl, cycloalkyl, -or Ri and R2 together with the atoms to which they are attached form a heterocyclic ring;
  • X, Y and Z are each independently hydrogen, halogen, -O-, -S-, -NR7-, or - CH 2 -;
  • R 7 is hydrogen or alkyl
  • R 9 is hydrogen, alkyl, or halogen
  • RA and RB are each independently hydrogen, alkyl, heteroalkyl, cycloalkyl, alkoxy, hemiacetal, ketal, or am amino acid; m is an integer from 1-4; and
  • A' is a pharmaceutically acceptable anion.
  • Embodiment 55 A compound of Formula (IVa): or a pharmaceutically acceptable salt thereof, wherein:
  • Ri and R2 are each methyl
  • X, Y, and Z are each either absent or -O-;
  • RA and RB are each independently hydrogen or methyl
  • A' is a pharmaceutically acceptable anion.
  • Embodiment 56 The compound of embodiment 54 or 55, wherein X is hydrogen and R3 is absent.
  • Embodiment 57 The compound of any of embodiments 54 to 56, wherein Y is hydrogen and R4 is absent.
  • Embodiment 58 The compound of any of embodiments 54 to 57, wherein Z is hydrogen and Rs is absent.
  • Embodiment 59 The compound of any of embodiments 54 to 58, wherein X is -O- and
  • R3 is alkyl
  • Embodiment 60 The compound of any of embodiments 54 to 59, wherein Y is -O- and
  • R 4 is alkyl
  • Embodiment 61 The compound of any of embodiments 54 to 60, wherein Z is -O- and
  • Embodiment 62 The compound of any of embodiments 54 to 61, wherein X is -O- and R3 is hydrogen.
  • Embodiment 63 The compound of any of embodiments 54 to 62, wherein Y is -O- and R 4 is hydrogen.
  • Embodiment 64 The compound of any of embodiments 54 to 63, wherein Z is -O- and Rs is hydrogen.
  • Embodiment 71 The compound of any one of embodiments 54 to 70, wherein RA and RB are hydrogen.
  • Embodiment 72 The compound of any one of embodiments 54 to 71, wherein R7 is hydrogen.
  • Embodiment 73 The compound of any of embodiments 54 to 72, wherein Ri and R2 are each independently hydrogen or alkyl.
  • Embodiment 74 The compounds of any one of embodiments 54 to 73, wherein Ri and R2 are alkyl, such as methyl.
  • Embodiment 76 The compound of any of embodiments 54 to 74, wherein Rio is -CHR7- O-aryl.
  • Embodiment 77 The compound of embodiment 54, wherein the compound is: Embodiment 78.
  • Embodiment 79 A compound of embodiment 1, having the structure of Formula Ila: or a pharmaceutically acceptable salt thereof, wherein:
  • Ri and R2 are methyl
  • X, Y, and Z are each either absent or -O-;
  • R3, R4, and Rs are each independently absent, hydrogen, or C1-C3 alkyl, wherein when R3 is present X is -O-, when R4 is present Y is -O-, and when Rs is present Z is - O-;
  • Re is hydrogen or C1-C3 alkyl, wherein at least one of R3, R4, and Rs are present and non-hydrogen, and wherein when Re is H, at least one of XR3 and ZRs are -O-(Ci-C3 alkyl).
  • Embodiment 80 The compound of embodiment 79, wherein at least two of R3, R4, Rs, and R c are present and non-hydrogen.
  • Embodiment 81 The compound of embodiment 79, wherein at least two of R3, R4, Rs are present and non-hydrogen.
  • Embodiment 82 The compound of embodiment 78, wherein m is 1.
  • Embodiment 83 The compound of any of embodiments 78-82, wherein Re is H.
  • Embodiment 84 The compound of any of embodiments 78-82, wherein Re is alkyl.
  • Embodiment 85 The compound of any of embodiments 78-84, wherein X is hydrogen and R3 is absent.
  • Embodiment 86 The compound of any of embodiments 78-85, wherein Y is hydrogen and R4 is absent.
  • Embodiment 87 The compound of any of embodiments 78-86, wherein Z is hydrogen and Rs is absent.
  • Embodiment 88 The compound of any of embodiments 78-87, wherein X is -O- and
  • R3 is alkyl
  • Embodiment 89 The compound of any of embodiments 78-88, wherein Y is -O- and
  • R4 is alkyl
  • Embodiment 90 The compound of any of embodiments 78-89, wherein Z is -O- and Rs is alkyl.
  • Embodiment 91 The compound of any of embodiments 78-90, wherein X is -O- and
  • R3 is hydrogen
  • Embodiment 92 The compound of any of embodiments 78-91, wherein Y is -O- and
  • R4 is hydrogen
  • Embodiment 93 The compound of any of embodiments 78-92, wherein Z is -O- and Rs is hydrogen.
  • Embodiment 94 The compounds of any one of embodiments 78 to 93, wherein Ri and R2 are each independently hydrogen or alkyl.
  • Embodiment 95 The compounds of any one of embodiments 78 to 94, wherein Ri and
  • R2 are alkyl.
  • Embodiment 96 The compound of embodiment 34, wherein the compound is:
  • Embodiment 97 A composition comprising a therapeutically effective amount of at least one compound of any of embodiments 1 to 96.
  • Embodiment 98 The composition of embodiment 97, further comprising a pharmaceutically acceptable excipient.
  • Embodiment 99 An oral dosage form comprising the composition of embodiments 96 and 97.
  • Embodiment 100 A method of treating post-traumatic stress disorder (PTSD) in a subject in need thereof, comprising administering a compound of any of embodiments 1 to 96 or a composition of any of embodiments 97 to 99 to the subject.
  • PTSD post-traumatic stress disorder
  • Embodiment 101 A method of treating depression in a subject in need thereof, comprising administering a therapeutically effective amount of a compound of any of embodiments 1 to 96 or a composition of any of embodiments 97 to 99 to the subject.
  • Embodiment 102 The method of embodiment 101, wherein the depression is a major depressive disorder (MDD) or treatment-resistant depression (TRD).
  • MDD major depressive disorder
  • TRD treatment-resistant depression
  • Embodiment 103 A method of treating an anxiety disorder in a subject in need thereof, comprising administering a therapeutically effective amount of a compound of any of embodiments 1 to 96 or a composition of any of embodiments 97 to 99 to the subject.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés représentés par la formule I, ou un sel pharmaceutiquement acceptable de ceux-ci, formule dans laquelle R1, R2, R3, R4, R5, R8, R9, X, Y, Z, W et m sont tels que définis dans la description. L'invention concerne également des compositions pharmaceutiques comprenant un composé de formule I ou un sel pharmaceutiquement acceptable de celui-ci et des excipients pharmaceutiquement acceptables, ainsi que des méthodes d'utilisation de ceux-ci, par ex., dans le traitement de maladies mentales et/ou troubles mentaux.<i />
PCT/US2024/038804 2023-07-19 2024-07-19 Nouveaux promédicaments et conjugués de diméthyltryptamine et leurs procédés d'utilisation Pending WO2025019800A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363514534P 2023-07-19 2023-07-19
US63/514,534 2023-07-19

Publications (1)

Publication Number Publication Date
WO2025019800A1 true WO2025019800A1 (fr) 2025-01-23

Family

ID=94282718

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/038804 Pending WO2025019800A1 (fr) 2023-07-19 2024-07-19 Nouveaux promédicaments et conjugués de diméthyltryptamine et leurs procédés d'utilisation

Country Status (1)

Country Link
WO (1) WO2025019800A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12396982B2 (en) 2020-05-08 2025-08-26 Atai Therapeutics, Inc. Compositions of matter and pharmaceutical compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10550140B2 (en) * 2014-02-25 2020-02-04 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of complement mediated disorders
US20220024956A1 (en) * 2020-02-04 2022-01-27 Mindset Pharma Inc. Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
WO2023078604A1 (fr) * 2021-11-05 2023-05-11 Cybin Irl Limited Formulations d'analogues de psilocybine et procédés d'utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10550140B2 (en) * 2014-02-25 2020-02-04 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of complement mediated disorders
US20220024956A1 (en) * 2020-02-04 2022-01-27 Mindset Pharma Inc. Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
WO2023078604A1 (fr) * 2021-11-05 2023-05-11 Cybin Irl Limited Formulations d'analogues de psilocybine et procédés d'utilisation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE PubChem 10 November 2021 (2021-11-10), "[3-[2-(Dimethylamino)ethyl]-4-hydroxyindol-1-yl]methylphosphonic acid", XP093267693, Database accession no. CID 156821129 *
DATABASE PubChem 23 March 2005 (2005-03-23), "Dimethyltryptamine | C12H16N2 ", XP093267663, Database accession no. CID 6089 *
VĂN THOẠI PHẠM, NAM NGUYEN HAI: "Design and Synthesis of Sustain-Acting Melatonin Prodrugs", JOURNAL OF CHEMISTRY, HINDAWI PUBLISHING CORPORATION, US, vol. 2013, 12 September 2013 (2013-09-12), US , pages 684760 - 6, XP093037623, ISSN: 2090-9063, DOI: 10.1155/2013/684760 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12396982B2 (en) 2020-05-08 2025-08-26 Atai Therapeutics, Inc. Compositions of matter and pharmaceutical compositions
US12472163B2 (en) 2020-05-08 2025-11-18 Atai Therapeutics, Inc. Compositions of matter and pharmaceutical compositions

Similar Documents

Publication Publication Date Title
US12065405B2 (en) Prodrugs and conjugates of dimethyltryptamine
US11845736B2 (en) Prodrugs of MDMA, MDA, and derivatives thereof
JP4497928B2 (ja) α７ニコチン性アセチルコリン受容体に対して親和性を有する１−アザビシクロＮ−ビアリールアミド
US11912680B2 (en) Nitric oxide releasing prodrugs of MDA and MDMA
US20240287107A1 (en) Prodrugs of dimethyltryptamine and derivatives thereof
WO2025019800A1 (fr) Nouveaux promédicaments et conjugués de diméthyltryptamine et leurs procédés d&#39;utilisation
PL90695B1 (fr)
US20080293685A1 (en) Spiro and other derivatives of diamondoids possessing therapeutic activity in the treatment of viral disorders
WO2024254411A2 (fr) Modulateurs de transporteurs monoaminergiques à base d&#39;amine de benzofurane propyle substitués
WO2024145464A2 (fr) Promédicaments d&#39;ibogaïne et de noribogaïne et procédés d&#39;utilisation
WO2025096895A1 (fr) Dérivés de carbamothioate et de carbamodithioate de mdma, mda ou de ses isomères optiquement actifs ((r)- ou (s)-mdma et mda
CN115427410A (zh) 酰胺或者磺酰胺类衍生物及其应用
WO2024145462A1 (fr) Analogues d&#39;ibogaïne et de noribogaïne et procédés d&#39;utilisation
WO2019192031A1 (fr) Dérivé de triptolide, son procédé de préparation et son utilisation
US20210323932A1 (en) Compositions for inhibition of histone demethylases and/or induction of tumor suppressor hexim1
CN117024397A (zh) 苯丙胺衍生物、其制备方法和应用
WO2022271969A2 (fr) Promédicaments d&#39;acylcarnitines
CN102675400A (zh) 3，16β-二胺基甾体季铵盐衍生物及其制备方法和应用
WO2008086678A2 (fr) Usage médical de lévophéncynonate comme agent neuroprotecteur
EP4619391A1 (fr) Dérivés de mescaline hétérocycliques fusionnés à n-propylamine substituée
WO2023086638A1 (fr) Modulateurs de l&#39;enpp1 et leurs utilisations
CN120398835A (zh) 一种激酶抑制剂化合物及其制备方法和用途
JPH04235127A (ja) 脳神経変性性疾患治療剤
BR112020008542B1 (pt) Derivado de triptolídeo e método de preparação do mesmo e uso do mesmo
O'DONNELL RIGID AMINO ACIDS RELATED TO ALPHA-METHYLDOPA.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24844032

Country of ref document: EP

Kind code of ref document: A1